The most common adverse outcome in platelet-rich plasma practice is not a bruise, an infection or a vascular event. It is a patient who is unhappy with a technically correct treatment because nobody told them what PRP does not do.
Tatiana Sarmiento puts the principle bluntly when teaching the facial indication: "The safety marketing is honest specificity on biological reality." Her list of what PRP does not accomplish is short, and every item on it is something patients arrive expecting.
This piece is written as a consultation script. The clinical content sits underneath it, but the deliverable is the set of sentences you say out loud before the patient commits.
The four things PRP is not
It is not a filler
"PRP does not restore lost structural volume," Tatiana teaches. "It does not create instant volume."
The mechanism explains itself once stated. A dermal filler occupies space — it is a physical implant with measurable volume and a rheological profile chosen to hold shape against tissue load. PRP is a small volume of the patient's own plasma carrying a signalling payload. The fluid itself is absorbed within days. Whatever effect follows is the result of cells responding to signal, not of material remaining in place.
So if the patient's concern is a hollow temple, a flattened midface, a deep nasolabial fold or a volume-deficient chin, PRP is the wrong tool and no number of sessions will change that. The underlying anatomy of that complaint is covered in Empire's material on facial volume loss.
It is not a facelift
"It cannot reposition tissue whatsoever."
Repositioning requires a mechanical vector — surgical release and redraping, or a suspension device. There is no mechanism by which an injected autologous fluid applies a directional force to a ptotic tissue plane. A patient who brings a photograph of themselves at thirty-five and points at their jawline is describing a repositioning problem.
It does not correct laxity
This is the most frequently blurred boundary, because laxity and skin quality are adjacent and the marketing language for both overlaps.
Improved dermal quality and improved dermal laxity are not the same endpoint. Collagen remodelling can change how skin looks and behaves at the surface — texture, tone, pore appearance, light reflection. It does not shorten a lax tissue envelope. If the assessment finding is redundancy rather than surface quality, the honest answer is that this is outside what PRP addresses.
It does not treat pigment
"It may improve the glow and the look of the skin looking healthy. But it is not going to treat melasma, and it is not going to treat any pigmentation."
This one needs care in the consultation, because patients frequently report that their skin "looks brighter," and that is a real perceptual change driven by texture and light scatter. It is not depigmentation. Melasma in particular is a chronic, relapsing, hormonally and UV-driven disorder of pigment production with its own treatment pathway, and offering PRP for it sets up a failure that is both predictable and avoidable.
What it does do — and why that is worth selling
Cutting the overclaim does not leave you with nothing. It leaves you with a defensible, specific indication.
PRP delivers platelet-derived signalling proteins into tissue. Those proteins — as Tatiana frames it, the signals that "regulate tissue response, angiogenesis and cellular communication" — support the repair and remodelling machinery already present in the dermis. The clinical result, when it arrives, is a change in skin quality: texture, tone, pore appearance and the diffuse optical property patients call luminosity.
Her own description of a typical result is more persuasive than any before-and-after claim: "You don't see any dramatic change, but you can tell the pores of the patient look closed, and the tone of the skin — the patient looks refreshed."
That is the honest product. It is a real product. It is best positioned for patients whose goal is skin quality rather than structural change, and it sits comfortably alongside the other collagen-directed options discussed in Empire's coverage of facial collagen stimulation.
Two timeline facts that belong in the same conversation
Nothing happens today
"You have to educate your patient that they don't expect to see anything in the same two or three hours of the same day. They need to wait one to two weeks — actually four weeks is best — to see that glow in the face."
This is not a caveat to mention at the end. It is a structural fact about the modality and it should be said before the patient books. A biostimulatory treatment has a latency because it works through cells, and cells work on a cellular timescale. A patient who expects a same-day change will assess the treatment as a failure within 48 hours, regardless of what happens at week four.
It is a series
"Results are gradual and often require a series of treatments. Usually it requires three or four sessions, one each month, because we want to target the collagen stimulation every month to get a healthy and long-lasting result."
Tatiana's facial cadence is three to four monthly sessions. Framing the first session as "a treatment" rather than "session one of a series" is the most common commercial mistake in PRP practice, because it converts a planned course into a single disappointing appointment.
These figures and intervals reflect Tatiana Sarmiento's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.
The consult script
What follows is a sequence, not a paragraph to recite. The order matters because each step narrows what the patient is expecting before you name a treatment.
1. Ask what they want changed, and make them point.
"Show me on your own face what bothers you." A patient who pulls upward at the temple and cheek is describing repositioning. A patient who pulls the skin taut is describing laxity. A patient who tilts toward the light and looks at their own cheek surface is describing quality. You have your answer before any discussion of modality.
2. Name the category, not the product.
"What you are pointing at is a volume question." Or: "What you are describing is a skin quality question." Categorising first prevents the conversation from becoming a negotiation about a brand name.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Functional & Regenerative Medicine courses — live patients, expert faculty, and ongoing mentorship.
3. If the category does not match PRP, say so and redirect immediately.
"PRP will not do that. It does not replace volume and it does not lift tissue. What addresses that is a different category of treatment, and we should talk about that instead." Redirect rather than adding PRP on top of the treatment they actually need — the comparison between biostimulatory and volumising approaches is set out in biostimulators vs fillers.
4. If the category does match, state the endpoint in the patient's own terms.
"What this is for is the quality of the skin surface — texture, tone, how light reflects off it. Patients describe it as looking refreshed. It is a subtle change, not a dramatic one."
5. State the timeline before price.
"You will not see anything for one to two weeks, and the best assessment point is around four weeks. It is a series of three to four sessions about a month apart."
6. Give them the scope list explicitly.
"So we are clear about what this is not: it will not add volume, it will not lift anything, it will not tighten loose skin, and it will not treat pigmentation or melasma."
7. Ask them to say it back.
"What are you expecting to see, and when?" If the answer contains the word "lift," or a date this week, the consultation is not finished.
8. Document it.
Record the endpoint discussed, the timeline given, the number of sessions planned, and the specific exclusions you named. This is the same discipline that applies to any consent conversation in aesthetic practice, and the principles in Empire's material on what to include in consent forms apply directly.
Why this conversation protects the practice
Three reasons, in ascending order of importance.
It prevents avoidable dissatisfaction. A correctly counselled patient who gets a subtle result at week four experiences success. An uncounselled patient who gets the identical result experiences failure.
It preserves the modality. Every patient who is sold PRP as a facelift and is disappointed tells other people that PRP does not work. The reputational damage attaches to the treatment, not to the clinic that oversold it.
It is the clinically correct thing to do. A patient whose actual problem is volume loss or tissue descent is not served by a course of injections that cannot address it, however well tolerated those injections are. Scope honesty is not a marketing tactic. It is the assessment doing its job.
Nothing here should be framed as a guarantee of any result. What you are promising is an accurate description of the mechanism, the endpoint and the timeline — not an outcome.
Empire's Platelet Rich Plasma Training covers preparation and facial and scalp application, and for the broader question patients are increasingly asking about regenerative options, see exosomes vs PDRN vs PRP.
Frequently Asked Questions
Does PRP add facial volume?
No. PRP is a small volume of the patient's own plasma carrying platelet-derived signalling proteins; the fluid itself is absorbed within days. It has no space-occupying effect and no rheological properties chosen to resist tissue load. A patient whose concern is a hollow temple, flat midface or volume-deficient chin needs a volumising approach, not PRP.
Can PRP tighten loose skin?
No. Improved dermal quality and corrected laxity are different endpoints. Collagen remodelling can change surface texture, tone and light reflection, but it does not shorten a lax tissue envelope or reposition descended tissue. If the assessment finding is redundancy rather than surface quality, PRP is not the treatment for it.
Does PRP treat melasma or pigmentation?
No. Patients often report that their skin looks brighter after PRP, which is a real perceptual change driven by texture and light scatter, not depigmentation. Melasma is a chronic, relapsing, hormonally and UV-driven pigment disorder with its own treatment pathway, and offering PRP for it sets up a predictable failure.
How soon do patients see a result from facial PRP?
Not the same day. The taught expectation is one to two weeks before anything is noticeable, with around four weeks being the better assessment point. The latency is structural — a biostimulatory treatment works through cells, on a cellular timescale — so a patient expecting a same-day change will judge the treatment as failed within two days.
How many PRP sessions does a facial course need?
The cadence taught here is three to four sessions at roughly monthly intervals, with the interval chosen to stimulate collagen repeatedly rather than once. Framing the first appointment as a standalone treatment rather than as session one of a planned series is the most common way a reasonable course becomes a disappointing single visit.
Disclaimer
This article reflects the clinical opinions and experience of Tatiana Sarmiento, Empire Medical Training faculty, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
